Law Seminars International has assembled leading government enforcers and policy makers from the Federal Trade Commission and Congress to provide an on-the-ground assessment of the new Washington challenges for pharmaceutical companies. Prominent in-house and outside counsel as well as industry executives will offer guidance on current competition issues facing the pharmaceutical industry and practical ways to handle key business decisions with potential antitrust hazards.
Attendees will learn how to determine antitrust exposure in the current legal and regulatory environment, how to identify and form pro-competitive mergers and joint ventures and how to approach a variety of transactions in order to maximize your products’ values without triggering expensive and time-consuming government actions or litigation. Additionally, this conference will provide practical insight on navigating government investigations and private litigation.
WilmerHale partner, Jim Burling, will speak on a panel entitled, "Maximizing the Life-Cycle of Products". This session will discuss lessons from recent cases: identifying antitrust risks, strategies for patent acquisition, Orange Book de-listing and end-of-life management; citizen petitions; authorized generics; agressive patent strategies while minimizing antitrust risks.